Oncodesign Services
Created in 1995
- BETA
Trend leader (A+)
Existing signals make this entity one of the most dynamic startups Social networks
1,196 12,139 1,472Activities
Technologies
Entity types
Location
20 Rue Jean Mazen, 21000 Dijon, France
Dijon
France
Employees
Scale: 11-50, 201-500
Estimated: 197
SIREN
399693811Engaged corporates
14
9 8Added in Motherbase
5 years, 7 months ago
biotech Value proposition
A leading CRO in drug discovery and preclinical services
Oncodesign Services is a Contract research organization (CRO) specializing in drug discovery and preclinical services.
Founded in 1995, Oncodesign Services mission’ is to contribute to the discovery of innovative therapies with unmet medical needs, in particular in oncology, inflammation and infectious diseases. From target identification, hit-to-lead and lead optimization to IND filing,
Oncodesign Services support the R&D programs of customers globally (whether pharmaceutical companies, biotechs, public research institutions, etc.).
Oncodesign Services offers a full spectrum of services in medicinal chemistry, DMPK, pharmaco-imaging, bioanalysis, in vivo/In vitro pharmacology (including humanized models). This continuum enables, either as stand-alone (SOLO) or as integrated (DRIVE) programs, the drug discovery of small molecule, molecular radiotherapy and biologicals entities.
As a pioneer in translational medicine to evaluate the efficacy of treatments, the company challenge relies on increasing throughput, minimizing timelines from bench to bedside while having a differential proposition of treatment for patients and therefore innovative science. For that, Oncodesign Services has been creating new technological pathways to find and select the best drug candidates.
Oncodesign Services has BSL1, BSL2 and BSL3 laboratories and all sites maintain the full AAALAC international accreditation for our animal care and use program.
Based in Dijon, France, in the heart of the university and hospital cluster, within the Paris-Saclay cluster and in Montreal, Canada, Oncodesign Services benefits from 15,000m2 of fully equipped chemistry and biologic laboratories. Oncodesign Services has 230 employees in France, United Kingdom, Germany, Canada and the United States, with highly competent in discovery research and translational pharmacology.
Kinase inhibitor Drug & Biomarker Discovery, Novel inflammatory target based drug discovery, Oncology advanced in vitro and in vivo pharmacology, Immunomodulation in oncology, DMPK/ADME, Medicinal chemistry, Bioanalysis, Translational Biomarkers, Biobanking, Biodecontamination/Biosafety, medicinal chemistry, drug discovery, drug analysis, Biopharma, Partnering, inflammatory diseases, infectious diseases, vitro assay development, and vivo modelsOriginal language
CRO spécialisée en drug discovery et services précliniques
Oncodesign Services est société de recherche contractuelle (CRO) spécialisée dans la découverte de médicaments et les services précliniques.
Fondée en 1995, Oncodesign Services a pour mission de contribuer à la découverte de thérapies innovantes, dans les domaines de l'oncologie, de l'inflammation et des maladies infectieuses. De l'identification de cible jusqu'au dépôt d'IND, Oncodesign Services accompagne les programmes R&D de clients internationaux (laboratoires pharmaceutiques, biotechs, instituts de recherche).
Oncodesign Services propose une gamme complète de services de drug discovery tels que la chimie médicinale, la DMPK, la pharmaco-imagerie, la bioanalyse, les tests in vivo/in vitro et les modèles de tumeurs. Nos capacités couvrent les petites molécules, les théranostiques et les nouvelles entités biologiques, soit par des projets autonomes (SOLO), ou par des programmes intégrés (DRIVE).
Pionnier en médecine translationnelle, le défi de l'entreprise repose sur une accélération des cadences pour un développement plus rapide – du laboratoire au patient – mais aussi sur l’élaboration d’une proposition thérapeutique différenciée et innovante. Pour cela, Oncodesign Services utilise de nouvelles voies technologiques pour identifier et sélectionner les meilleurs candidats médicaments.
Oncodesign Services dispose de laboratoires BSL1, BSL2 et BSL3 et tous les sites maintiennent l'accréditation internationale AAALAC de notre programme de soin et d'utilisation des animaux.
Basé à Dijon, au sein du pôle Paris-Saclay et à Montréal, Oncodesign Services bénéficie de 2000m2 de laboratoires de chimie et biologie à la pointe de la technologie. Oncodesign Services compte 230 collaborateurs en France, au Canada et aux Etats-Unis, avec de hautes compétences en drug discovery et pharmacologie translationnelle.
Oncodesign Services - CRO in Drug discovery
Oncodesign Services is a CRO specializing in drug discovery & preclinical services, in oncology, inflammation and infectious diseases.
https://www.oncodesign-services.com/
| Corporate | Type | Tweets | Articles | |
|---|---|---|---|---|
 Eisai Co., Ltd. Pharmaceutical | Eisai Co., Ltd. Pharmaceutical | Other 9 Feb 2024 | | |
 Eurazeo Finance, Financial Services | Eurazeo Finance, Financial Services | Other 22 Jan 2024 | | |
 Dijon métropole Government Administration, French metropolis | Dijon métropole Government Administration, French metropolis | Not capitalistic Partnership Event 21 May 2021 23 May 2024 | | |
 Région Bourgogne-Franche-Comté National and local authorities, Government Administration | Région Bourgogne-Franche-Comté National and local authorities, Government Administration | Other 16 Mar 2024 | | |
 Business France National and local authorities, Government Administration | Business France National and local authorities, Government Administration | Not capitalistic Not partnership Event 3 Feb 2020 | | |
 SOCFIM Bank, Banking | SOCFIM Bank, Banking | Other 21 Sep 2018 | | |
 Servier Pharmaceuticals Pharmaceutical, Pharmaceutical Manufacturing | Servier Pharmaceuticals Pharmaceutical, Pharmaceutical Manufacturing | Not capitalistic Partnership Not event 25 Dec 2022 | | |
 France Biotech Startup accelerator & VC, Biotechnology, Biotechnology Research | France Biotech Startup accelerator & VC, Biotechnology, Biotechnology Research | Not capitalistic Partnership Event 18 Mar 2024 | | |
 Medicen Paris Region Public business cluster, French Cluster, Civic and Social Organizations | Medicen Paris Region Public business cluster, French Cluster, Civic and Social Organizations | Other 18 Oct 2019 11 Mar 2024 | | |
 CEA Research | CEA Research | Other 26 Nov 2021 | | |